Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation

European Neuropsychopharmacology

Volumn 19, Issue 7, 2009, Pages 457-465

  Blier, Pierre ^a,b   Gobbi, Gabriella ^a   Turcotte, Julie E ^a   de Montigny, Claude ^a   Boucher, Nathalie ^a   Hébert, Chantal ^b   Debonnel, Guy ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

2 adrenoceptor; Augmentation; Norepinephrine; Reuptake inhibition; Serotonin; Treatment resistance

Indexed keywords

MIRTAZAPINE; PAROXETINE;

ADULT; ANOREXIA; ANXIETY; APATHY; APPETITE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIGRAINE; MONOTHERAPY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; TREMOR; URTICARIA; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPLIANCE; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ELECTROCHEMISTRY; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 67349189432     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.01.015     Document Type: Article

References (31)

1. Ballesteros J., and Callado L.F. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J. Affect. Disord. 79 (2004) 137-147
2. Benkert O., Szegedi A., and Kohnen R. Mirtazapine compared with paroxetine in major depression. J. Clin. Psychiat. 6 (2000) 656-663
3. Besson A., Haddjeri N., Blier P., and de Montigny C. Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur Neuropsychopharmacol. 10 (2000) 177-188
4. Bergeron R., and Blier P. Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. Am. J. Psychiat. 151 (1994) 1084-1086
5. Carpenter L.L., Yasmin S., and Price L.H. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol.Psychiat. 51 (2002) 183-188
6. Chaput Y., de Montigny C., and Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology 5 (1991) 219-229
7. Coupland N.J., Bailey J.E., Potokar J.P., and Nutt D.J. 5-HT3 receptors, nausea, and serotonin reuptake inhibition. J. Clin. Psychopharmacol. 17 (1997) 142-143
8. Crossley N.A., and Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J. Clin. Psychiat. 68 (2007) 935-940
9. Dremencov E., El Mansari M., and Blier P. Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol.Psychiat. 61 (2007) 671-678
10. Haddjeri N., Blier P., and de Montigny C. Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J. Pharmacol. Exp. Ther. 277 (1996) 861-871
11. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiat. 23 (1960) 56-62
12. Hatanaka K., Yatsugi S., and Yamaguchi T. Effect of acute treatment with YM992 on extracellular norepinephrine levels in the rat frontal cortex. Eur. J. Pharmacol. 395 (2000) 31-36
13. Judd L.L., Paulus M.J., Schettler P.J., Akiskal H.S., Endicott J., Leon A.C., Maser J.D., Mueller T., Solomon D.A., and Keller M.B. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am. J. Psychiat. 157 (2000) 1501-1504
14. Kennedy S.H., Eisfeld B.S., Meyer J.H., and Bagby R.M. Antidepressants in clinical practice: limitations of assessment methods and drug response. Hum. Psychopharmacol. 16 (2001) 105-114
15. Lin E.H., Von Korff M., Katon W., Bush T., Simon G.E., Walker E., and Robinson P. The role of the primary care physician in patients' adherence to antidepressant therapy. Med. Care 33 (1995) 67-74
16. Maes M., Libbrecht I., van Hunsel F., Campens D., and Meltzer H.Y. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J. Clin. Psychopharmacol. 19 (1999) 177-182
17. Melfi C.A., Chawla A.J., Croghan T.W., Hanna M.P., Kennedy S., and Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch. Gen. Psychiat. 55 (1998) 1128-1132
18. Montgomery S.A., and Asberg M. A new depression scale designed to be sensitive to change. Br. J.Psychiat. 134 (1979) 382-389
19. Nelson J.C., Mazure C.M., Jatlow P.I., Bowers Jr. M.B., and Price L.H. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol. Psychiat. 55 (2004) 296-300
20. Nemeroff C.B., Entsuah R., Benattia I., Demitrack M., Sloan D.M., and Thase M.E. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol. Psychiat. 63 (2008) 424-434
21. Paykel E.S., Ramana R., Cooper Z., Hayhurst H., Kerr J., and Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol. Med. 25 (1995) 1171-1180
22. Rouillon F., and Gorwood P. The use of lithium to augment antidepressant medication. J. Clin. Psychiat. 59, Suppl 5 (1998) 32-39
23. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E., Ritz L., Biggs M.M., Warden D., Luther J.F., Shores-Wilson K., Niederehe G., Fava M., and STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med. 354 (2007) 1231-1242
24. Sanacora G., Berman R.M., Cappiello A., Oren D.A., Kugaya A., Liu N., Gueorguieva R., Fasula D., and Charney D.S. Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response. Neuropsychopharmacology 29 (2004) 1166-1171
25. Shams M., Hiemke C., and Härtter S. Therapeutic drug monitoring of the antidepressant mirtazapine and its N-demethylated metabolite in human serum. Ther. Drug Monit. 26 (2004) 78-84
26. Szabo S.T., and Blier P. Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. Brain Res. 922 (2001) 9-20
27. Szabo S.T., and Blier P. Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons. J. Pharmacol. Exp. Ther. 302 (2002) 983-991
28. Szegedi A., Müller M.J., Anghelescu I., Klawe C., Kohnen R., and Benkert O. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J. Clin. Psychiat. 64 (2003) 413-420
29. Trivedi M.H., Rush A.J., Pan J.Y., and Carmody T.J. Which depressed patients respond to nefazodone and when?. J. Clin. Psychiat. 62 (2001) 158-163
30. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., Shores-Wilson K., Biggs M.M., Balasubramani G.K., Fava M., and STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiat. 163 (2006) 28-40
31. Young E.A., Kornstein S.G., Marcus S.M., Harvey A.T., Warden D., Wisniewski S.R., Balasubramani G.K., Fava M., Trivedi M.H., and Rush A.J. Sex differences in response to citalopram: A STAR *D report. J. Psychiat. Res. 43 (2009) 503-511